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Abstract Hybrid cardiac single photon emission computed
tomography (SPECT)/CT imaging allows combined assess-
ment of anatomical and functional aspects of cardiac disease.
In coronary artery disease (CAD), hybrid SPECT/CT imaging
allows detection of coronary artery stenosis and myocardial
perfusion abnormalities. The clinical value of hybrid imaging
has been documented in several subsets of patients. In selected
groups of patients, hybrid imaging improves the diagnostic
accuracy to detect CAD compared to the single imaging tech-
niques. Additionally, this approach facilitates functional inter-
rogation of coronary stenoses and guidance with regard to
revascularization procedures. Moreover, the anatomical infor-
mation obtained from CT coronary angiography or coronary
artery calcium scores (CACS) adds prognostic information
over perfusion data from SPECT. The use of cardiac hybrid
imaging has been favoured by the dissemination of dedicated
hybrid systems and the release of dedicated image fusion
software, which allow simple patient throughput for hybrid
SPECT/CT studies. Further technological improvements such
as more efficient detector technology to allow for low-radiation
protocols, ultra-fast image acquisition and improved low-noise
image reconstruction algorithms will be instrumental to further
promote hybrid SPECT/CT in research and clinical practice.
Keywords Myocardial perfusion SPECT . Coronary CT
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Introduction
Non-invasive cardiac imaging has witnessed tremendous
advances in the last few decades. This holds true particularly
for techniques to detect coronary artery disease (CAD)
which are currently used for the diagnosis, prognostication
and risk stratification of patients with known or suspected
CAD. As a result, the number of non-invasive cardiac im-
aging tests has steadily increased over the last few years [1].
This has driven the dissemination of state-of-the art high-end
devices for computed tomography (CT) and nuclear cardiol-
ogy worldwide.
Besides morphological CAD, functional consequences of
coronary stenoses on myocardial perfusion and metabolism
are relevant. Additionally, other entities such as microvascular
or endothelial dysfunction have been recognized to contribute
significantly to disease pathology [2, 3]. Hence, clinical car-
diac imaging is increasingly challenged to address in a com-
prehensive manner the anatomical and functional aspects of
CAD in order to provide guidance for appropriate medical or
interventional therapies.
Hybrid imaging has achieved increasing clinical accep-
tance because it provides anatomical information on the
presence of coronary artery lesions combined with functional
information on its pathophysiological consequences with re-
gard to myocardial perfusion or metabolism. The present
review provides an overview on the most important clinical
aspects of cardiac single photon emission computed tomog-
raphy (SPECT)/CT hybrid imaging touching upon the clini-
cal need and the technical requirements. We provide an
overview of relevant literature highlighting the clinical value
and addressing potential indications and pitfalls of cardiac
hybrid imaging. Finally, as research is ongoing and the tech-
nique is continuously expanding to other indications we will
provide a glimpse into potential future clinical avenues of
hybrid imaging.
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Clinical background
There is poor agreement between the degree of stenosis of a
coronary lesion and the presence of myocardial ischaemia. A
number of studies using intraoperative Doppler ultrasound,
positron emission tomography (PET) and fractional flow re-
serve (FFR) have consistently demonstrated that the angio-
graphic severity of coronary lesions is a poor predictor of its
haemodynamic relevance [4–7]. Similarly, comparative stud-
ies of CT coronary angiography (CTCA) and myocardial
perfusion imaging (MPI) showed that only 30–50 % of ste-
noses with more than 50 % luminal narrowing are associated
with reversible perfusion defects on MPI, and conversely
many patients with completely normal myocardial perfusion
may harbour subclinical CAD [8–11].
Large randomized clinical trials have failed to demonstrate
superiority of revascularization over modern medical treat-
ment in terms of long-term cardiovascular events if patients
are not stratified by prior ischaemia testing [12, 13]. Reducing
the ischaemic burden of the left ventricular (LV) myocardium
seems to improve the outcome of stable CADpatients [14, 15].
The pivotal role of ischaemia-targeted revascularization has
further been highlighted in the randomized FAME I trial [16].
Finally, the FAME II trial has proven—for the first time in a
prospective randomized study—superiority of revasculariza-
tion over optimal medical treatment for patients with flow-
limiting coronary stenoses (FFR <0.80) [17]. Similar large
prospective randomized trials with non-invasive imaging in-
stead of FFR are currently enrolling patients [18]. Consequent-
ly, tests for myocardial ischaemia are incorporated into current
revascularization guidelines, beyond the assessment of coro-
nary morphology alone [19].
Thus, functional interrogation of coronary lesions is feasi-
ble with FFR during invasive coronary angiography and has
gained wide acceptance based on the solid evidence published
in favour of the technique. However, a non-invasive anatom-
ical and functional assessment of CAD should be preferred as
first-line test in the majority of patients with suspected CAD in
order to reduce procedure-related morbidity and costs [20].
CTFFR was recently developed as a method to determine
haemodynamic relevance of coronary lesions from standard
CT angiograms using computational fluid dynamics. This
technique is still experimental and a recent study has shown
limitations of this technique in routine clinical practice [21].
CT coronary angiography
Accuracy for detection of coronary artery stenosis
The diagnostic performance of CTCA as compared to inva-
sive coronary angiography has been documented in various
studies [22] and recently also in meta-analyses [23]. The latter
revealed a pooled area under the receiver-operating character-
istic curve of 0.99 for diameter stenoses >50 %. Pooled
sensitivity and specificity were 99 and 89 %, respectively
[24, 25]. The available data consistently document excellent
diagnostic performance of CTCA for identifying and ruling
out coronary artery stenoses >50 % when compared to inva-
sive coronary angiography.
Early studies on CTCA reported effective radiation dose
levels up to 20 mSv when using spiral acquisitions with
retrospective ECG gating. However, current radiation dose
levels are far lower, owing to the development and application
of sequential and high-pitch scans [26] as well as to the use of
lower tube voltage settings and iterative reconstructions [27].
Currently, effective radiation dose levels of CTCA are in the
range of 1–5 mSv. Given the more widespread application of
CTCA with increasing numbers of examinations worldwide,
this dose reduction is important for patient safety, particularly
if hybrid imaging protocols are considered.
While robustness and stability of CTCA continues to im-
prove with each CT technology development, giving rise to
improved temporal and spatial resolution in in vitro studies
[28] and a reduction of image noise when using iterative
reconstructions [29], CTCA still does not perform well at high
and irregular heart rates, in morbidly obese patients, in pa-
tients with stents and in cases of severe coronary calcifica-
tions. Each of these features may result in a non-diagnostic
CTCA study, precluding its application in these patients.
Plaque detection and characterization
Being a cross-sectional imaging modality, CTCA depicts the
coronary wall including plaques in addition to stenoses. Most
studies so far have focused on a simple categorization scheme
of coronary plaques as non-calcified, partially calcified and
calcified. By doing so, authors found a good agreement between
CTCA and intravascular ultrasound representing the clinical
reference standard modality for plaque characterization. Still,
this current way of plaque classification based on CTCA falls
short of a more advanced description of plaque characteristics,
such as the identification of thin-cap fibroatheromas which are
believed to represent late stage and potentially vulnerable cor-
onary plaques. Recently, Maurovich-Horvat and colleagues
described in their in vitro studies a “napkin-ring” sign plaque
in coronary arteries, representing a ring of hyperattenuation
surrounding a low attenuating centre [30]. This plaque type
was highly predictive of thin-cap fibroatheroma as determined
by histopathology [30–32]. Interestingly, a recent in vivo study
demonstrated that the napkin-ring sign plaque depicted with
CTCA was strongly associated with future acute coronary
syndrome events, being independent of other high-risk coro-
nary CTCA features [33]. While these recent studies are
highly promising, the current clinical role of coronary plaque
characterization with CTCA has still not been defined. Further
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improvements in spatial and contrast resolution are required
for a better anatomical depiction and differentiation of the
various plaque types.
Myocardial perfusion SPECT
Myocardial perfusion can be assessed using radionuclide im-
aging studies such as SPECT or (in more specialized centres)
PET. With SPECT a vast amount of data is available demon-
strating its excellent diagnostic accuracy for detecting angio-
graphically significant CAD with a sensitivity and specificity
of 87–89 % and 73–75 %, respectively, depending on the
choice of radionuclide and stress modality [34]. Gated SPECT
offers information of LV volumes and ejection fraction. A
large body of evidence documents the prognostic value of
SPECT with a consistent <1 % cardiac event rate for patients
with completely normal perfusion on SPECT [35]. Current
software packages allow semiquantitative assessment of per-
fusion defect extent in relation to the total LV myocardium.
Based on these quantitative measures of ischaemic burden,
SPECT has demonstrated its value for guiding revasculariza-
tion procedures in CAD patients [15, 19, 36]. In patients with
ischaemia extending over ≥10 % of the left ventricle, a revas-
cularization procedure improves the outcome, while in patients
with <10 % medical therapy is equivalent or better. Finally,
SPECT provides three-dimensional (3-D) data sets as CTCA
(in DICOM). These data sets can be easily superimposed onto
CT images (after correcting for the lower matrix size and
bigger voxel size) using dedicated fusion software.
Again, radiation exposure is a concern, particularly with
SPECT and SPECT/CT. However, low-dose SPECT is feasi-
ble with novel solid-state detector cameras and improved
iterative image reconstruction algorithms with effective radi-
ation doses in the range of 4–7 mSv [37, 38]. Further reduc-
tion to <2 mSv is achievable if stress protocols are performed
first and rest images are not required. Other functional modal-
ities [stress echocardiography, stress cardiac magnetic reso-
nance imaging (CMR)] are potentially attractive candidates
for hybrid imaging. Both modalities avoid ionizing radiation;
however, the two-dimensional image format of echocardio-
grams is unsuitable for fusion with CTCA. Stress CMR/
CTCA fusion may be possible using fast perfusion sequences
and is currently under clinical investigation [39–41].
Hybrid systems
The first hybrid devices were PET/CT tomographs which
gained wide acceptance in oncology for the staging of neo-
plastic disease. Along this path, similar hybrid devices com-
bining SPECTcameras with high-end CT devices and recently
also first experimental hybrid PET/MR have been released.
Figure 1 gives an overview of commercially available hybrid
SPECT/CT devices from different manufacturers. Some of
these devices offer attractive features for hybrid imaging.
The Discovery NM/CT 570c consists of a small footprint-
dedicated cardiac SPECT camera equipped with solid-state
semiconductor detector technology andmulti-pinhole collima-
tors. This novel assembly combined with the unique geometry
results in an exceptionally high photon sensitivity [37]. It
allows shortened acquisition times to 5 min or less [42] and
thereby improves patient comfort and throughput for hybrid
imaging. The Siemens Symbia TruePoint System is equipped
with intelligent collimators that track and centre the heart to
improve count sensitivity. The AnyScan SPECT/CT system
from Mediso Medical Imaging Systems (Budapest, Hungary)
is equipped with a 16-slice CT and can be upgraded to a
SPECT/PET/CT hybrid system. The majority of these hybrid
devices are available with high-end CT devices; however, it
should be emphasized that for coronary CT angiography the
recommended minimum number of slices is 64. CT machines
having less slices have a temporal and spatial resolution
that is not high enough to provide a diagnostic image
quality of all coronary segments in a sufficient number of
patients.
The majority of novel SPECT/CT systems offer improved
image reconstruction techniques [37]: These novel algorithms
are largely based on modelling the specific geometry of the
detectors and the collimator to improve count sensitivity.
Furthermore, most systems offer compensation for image
resolution loss by accelerated iterative reconstruction. Several
manufacturers have taken this approach [e.g. wide beam re-
construction (WBR) by UltraSpect Ltd., Haifa, Israel; Aston-
ish by Philips, Best, The Netherlands; IQ SPECT by Siemens,
Erlangen, Germany; and Evolution by GE Healthcare, Mil-
waukee, WI, USA]. With these improved reconstruction tech-
niques, further reductions in image acquisition times or radi-
ation may be achieved [43].
Post-processing and image analysis software
In the setting of cardiac hybrid imaging the use of hybrid
systems is not necessarily required and less important than
for oncology whole-body PET/CT. Nonetheless, in cardiac
SPECT/CT imaging, manual superposition and individual
correction of data set misalignment is crucial to ensure ade-
quate quality for several reasons: cardiac and respiratory mo-
tion, intrinsic disagreement in the size and shape of the left
ventricle between non-gated SPECT images (unfortunately
gated SPECT images are too noisy for hybrid imaging) and
diastole-gated CTCA and 3-D instead of cross-sectional dis-
play of fused data sets. Therefore, cardiac hybrid imaging can
easily be performed by acquiring data sets on stand-alone
systems with subsequent software-based fusion, and in fact
this set-up may allow exploitation of the full capacity of the
Eur J Nucl Med Mol Imaging (2014) 41 (Suppl 1):S91–S103 S93
respective systems for all kinds of medical purposes rather
than having a highly dedicated hybrid device.
Dedicated software packages are available from different
manufacturers/research institutions that allow fusion of CTCA
and radionuclide images (Fig. 2) [44]. A crucial element is a
user interface that permits correction of misalignment between
data sets. The remaining fusion steps include tracking of the
coronary arteries (by the same methods as standard CTCA
software) and modelling of the perfusion data into a 3-D
volume rendering of the left ventricle. Current software pack-
ages allow fusion of images from different modalities and
even different manufacturers. In experienced hands and with
image data sets of reasonable quality, the image fusion process
takes no longer than 5 min per patient. Additional reconstruc-
tion tools that eliminate the influence of cardiac LV motion in
the display and freeze myocardial perfusion information in a
diastolic frame (“motion-frozen” technique) may further facil-
itate image fusion [45].
Clinical value of hybrid imaging
Table 1 shows a summary of available diagnostic studies with
cardiac hybrid imaging. The feasibility and clinical robustness
of non-invasive hybrid imaging was first documented by
Namdar and co-workers in a clinical study involving fusion
of 13N-NH3 PETwith 4-slice CTCA in 25 patients with CAD
[46]. These encouraging results were replicated with SPECT/
CT in a study by Rispler and co-workers who documented an
increase in specificity (from 63 to 95 %) and positive
predictive value (PPV, from 31 to 77 %) with SPECT/CTCA
compared to CTCA alone [47]. Sato and co-workers showed
that adding SPECT information in non-evaluable arteries on
CTCA improved particularly specificity and PPV significant-
ly (from 80 to 92 % and from 69 to 85 %, respectively) [48].
Notably, the majority of non-evaluable severely calcified ves-
sels in the left anterior descending artery were positive on
stress nuclear MPI, whereas the majority of non-evaluable
vessels with motion artefacts in the right coronary artery were
negative. One of the largest, recently published studies includ-
ed 107 patients undergoing hybrid 15O-H2O PET/64-slice
CTCA [49]. In this study, haemodynamic significance of
coronary stenoses was confirmed in 18 of 40 patients with
FFR providing a more comprehensive gold standard. Conse-
quently, the use of PET/CTCA increased the PPV significant-
ly from 76 to 96 % compared to CTCA alone.
However, a number of limitations apply to the aforemen-
tioned studies including the limited number of patients, the
variety of hybrid systems used and the lack of a uniform
gold standard. Three studies have specifically addressed the
incremental value of hybrid cardiac imaging over the side-
by-side analysis of CTCA and myocardial perfusion images
(Table 2) in patients with multivessel disease (MVD), inter-
mediate severity coronary stenoses and/or side branch disease
[45, 50, 51]. Hence, hybrid cardiac imaging may facilitate the
identification of haemodynamically significant coronary ar-
tery stenoses and thereby guide clinicians on the appropriate
method of revascularization. Moreover, in intermediate steno-
ses, a hybrid study may accurately confirm or rule out their
haemodynamic significance and thereby reduce the number of
Fig. 1 Commercially available
hybrid SPECT/CT systems by
different manufacturers. a
Discovery NM/CT 570c by GE
Healthcare. b Symbia TruePoint
SPECT/CT by Siemens
Healthcare, Erlangen, Germany.
c BrightView XCT system by
Philips Healthcare, Best, The
Netherlands. (d) AnyScan
SPECT/CT system from Mediso
Medical Imaging Systems,
Budapest, Hungary
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potentially unnecessary stent implantations, a key cost driver
in cardiovascular medicine.
A recent study including more than 500 patients has also
documented the prognostic value of hybrid imaging [52]. In
this study, CTCA stenoses provided independent prognostic
information over SPECT alone. Moreover, the presence of
non-calcified plaque emerged as an independent predictor
along with CTCA stenoses and abnormal SPECT. Further
Fig. 2 The main steps of SPECT/CT image fusion (CardIQ Fusion,
Advantage Workstation, GE Healthcare). a Image coregistration . This
first step is crucial and allows the user to align the images on axial, sagittal
and coronal image planes in order to obtain optimal matching of structural
and functional information. b Definition of LV epicardium . This proto-
col displays a view containing the segmented CT LVepicardium using the
conventional volume rendering technique, allowing addition or removal
of structures from the LV epicardium if needed. In each point of the
surface of the volume rendered image the colour is computed as being the
maximum perfusion intensity on a ray going from the particular point to
the centre of the heart on CT. c Coronary tree segmentation . This
protocol allows the user to grow the coronary arteries from the ascending
aorta using automatic vessel tracking or manual segmentation. d 3-D
volume rendered fusion images . As the final step, the hybrid display
protocol displays a volume rendering containing the LV epicardial vol-
ume, the volume rendered coronary tree, and the left and right heart
chambers acquired by an automatic segmentation algorithm. (Reprinted
with permission from Springer [44])
Table 1 Added diagnostic accuracy of cardiac hybrid imaging (SPECT/CTCA and PET/CTCA) (vessel-based analysis)
Author Hybrid system n Gold standard (definition of significant CAD) Sens Spec PPV NPV
Namdar et al. (2005) [46] 13N-NH3 PET/4-slice CTCA 25 Flow-limiting coronary stenoses requiring
revascularization (ICA+PET)
90 98 82 99
Rispler et al. (2007) [47] SPECT/16-slice CTCA 56 Flow-limiting coronary stenoses
(>50 % stenosis on ICA+SPECT pos.)
96 95 77 99
Groves et al. (2009) [82] 82Rb PET/64-slice CTCA 33 >50 % stenosis on ICA 88 100 97 99
Sato et al. (2010) [48] SPECT/64-slice CTCAa 130 >50 % stenosis on ICA 94 92 85 97
Kajander et al. (2010) [49] 15O-H2O PET/64-slice CTCA 107 Flow-limiting coronary stenosis
(>50 % stenosis of ICA+FFR)
93 99 96 99
n number of patients in each study, SPECT single photon emission computed tomography, CTCA CT coronary angiography, PET positron emission
tomography, CAD coronary artery disease, Sens sensitivity, Spec specificity, PPV positive predictive value, NPV negative predictive value, ICA
invasive coronary angiography, FFR fractional flow reserve
a Hybrid SPECT/CTCA only applied for non-evaluable arteries on CTCA (14 %)
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prognostic information is provided by the spatial superposi-
tion of perfusion defects and coronary CTstenosis [53]. In this
study, 324 consecutive patients undergoing hybrid SPECT/
CTCA were subdivided into three groups: (1) stenosis by
CTCA and matching reversible SPECT defect (i.e. the perfu-
sions defect was superimposed on the stenotic coronary artery
on the hybrid 3-D display), (2) unmatched CTCA and SPECT
finding and (3) normal finding by CTCA and SPECT. On
follow-up (median 2.8 years), a corresponding matched hy-
brid finding was associated with a significantly higher event
rate [death or myocardial infarction (MI)] and proved to be an
independent predictor for major adverse cardiovascular events
(MACE). The annual death/MI rate was 6.0, 2.8 and 1.3 % for
patients with matched, unmatched and normal findings.
Two further studies have proven that hybrid imaging has
an impact on downstream resource utilization and most no-
tably on revascularization rates. Pazhenkottil et al. reported
that revascularization rates within 60 days were 41, 11 and
0 % for matched, unmatched and normal findings, respective-
ly (p <0.001) [54]. In a similar study by Schaap and col-
leagues, revascularization rates were even higher with 90, 31
and 0 % for matched, unmatched and normal findings, respec-
tively (p <0.001) [55]. These results should be highlighted in
the context of the recent SPARC study which documented a
surprisingly modest impact of stand-alone non-invasive im-
aging modalities on downstream resource utilization with 38–
61 % of patients with the most severe abnormalities on CTCA
or perfusion scans not being referred for invasive angiography
[56]. Thus, it appears that the combined anatomical and func-
tional assessment of CAD by hybrid imaging may encourage
guideline-concordant patient management among physicians
ordering those tests.
Clinical indications for hybrid imaging
Open questions remain as to which patients benefit from
integrated hybrid imaging. It appears that the vast majority
of patients referred for non-invasive cardiac imaging studies
to exclude or confirm the presence of CAD are adequately
addressed with one single study (i.e. either CTCA or func-
tional imaging test). Additionally, the increased radiation and
higher costs of hybrid imaging studies have to be considered
as an important factor. Therefore, patients should be carefully
selected where an added value of hybrid imaging may be
anticipated.
Intermediate pretest likelihood
The pretest likelihood of CAD can be assessed based on the
age and gender of the subject, the typicality of chest pain and
the ECG changes on exercise testing [57]. Patients with inter-
mediate pretest likelihood are more likely to yield intermedi-
ate or inconclusive results in one of the imaging studies, e.g.
intermediate coronary stenosis on CTCA. In this situation, an
additional perfusion study may address the haemodynamic
relevance of such lesions and help to decide whether the
patient can be treated medically or needs to be referred for
invasive angiography with revascularization. Such sequential
hybrid imaging protocols have been implemented in several
centres with hybrid imaging capabilities. However, beta
blockers given prior to the CTCA study may affect the sub-
sequent SPECT study by blunting perfusion defect extent and
reversibility, and vasodilator stress protocols should be pre-
ferred over exercise or dobutamine whenever the CTCA study
precedes the SPECT [58, 59]. Likewise, CT tomographs
having a high temporal resolution obviating the need for beta
blocker administration prior to the imaging study are
preferred.
Multivessel disease
Patients with MVD represent a population that is at increased
risk for future cardiac events and therefore is often referred for
revascularization to improve outcomes. However, the major-
ity of patients with angiographic three-vessel disease turn out
Table 2 Synergistic clinical value of fused hybrid imaging compared to the side-by-side analysis
Author Hybrid system Patient population Incremental value of fused hybrid imaging
Gaemperli et al. (2007) [50] SPECT/64-slice CTCA
and 3-D image fusion
38 patients with ≥1
SPECT defect
Modification of initial interpretation in 29 % of
patients. In equivocal lesions, haemodynamic
relevance could be confirmed in 35 % and
excluded in 25 %
Santana et al.(2009) [51] 16- and 64-slice CTCA and
MPI (SPECT or 82Rb PET)
50 patients with
suspected CAD
Modification of initial interpretation in 28 % of
patients. Trend towards increased sensitivity
(by 17 %) in patients with MVD
Slomka et al. (2009) [45] Motion-frozen SPECT/64-slice
CTCA (automatic coregistration)
35 patients with
suspected CAD
Improved diagnostic performance in RCA and
LCX territories
SPECT single photon emission computed tomography, CTCA CT coronary angiography, MPI myocardial perfusion imaging, PET positron emission
tomography, CAD coronary artery disease, RCA right carotid artery, LCX left circumflex artery
S96 Eur J Nucl Med Mol Imaging (2014) 41 (Suppl 1):S91–S103
to have considerably less flow-limiting lesions than suspected
from their angiograms [7]. Compared to perfusion imaging
alone, hybrid imaging may have an incremental diagnostic
value to identify haemodynamically significant lesions partic-
ularly in patients with MVD (Fig. 3) [51]. By this means,
hybrid imaging may allow targeted revascularization proce-
dures in MVD patients avoiding stent or bypass overuse with
the inherent adverse sequelae of stent or graft reocclusion.
Significant side branch disease
Side branches are often regarded as prognostically insignificant
but may be associated with significant angina. Although perfu-
sion defects in side branch disease are generally smaller, they
may be difficult to distinguish from main branch disease. Hy-
brid imaging provides accurate coregistration of coronary anat-
omy and perfusion defects and therefore allows identifcation of
flow-limiting lesions in side branches (diagonal, posterolateral
branches) for targeted revascularization procedures [50]
(Fig. 4).
Chronic total occlusions
Percutaneous revascularization procedures in patients with
chronic total occlusions (CTO) are associated with higher rates
of complications and larger contrast media and radiation ad-
ministration. Therefore, proof of myocardial ischaemia in the
territory of the occluded vessel is mandatory prior to
embarking on any potentially harmful intervention. On the
one hand, hybrid imaging may accurately detect a perfusion
defect located in the territory of the CTO vessel. On the other
hand, anatomical CT information such as the morphology of
the stump, the presence of side vessels, the length of occlusion
and/or calcifications or the presence of tortuosity are predictors
A
B C
D E
Fig. 3 Example of a 59-year-old
gentleman with three-vessel
disease who underwent stenting
of the right coronary artery a few
months prior to his hybrid
SPECT/CT study. Angiography
revealed a long 80 % stenosis of
the mid left anterior descending
artery and a 70 % stenosis of the
proximal left circumflex artery
(LCX) which was confirmed on
CTCA (yellow arrows , c).
SPECT showed a partially
reversible perfusion defect (white
arrows) of the inferolateral wall
(a stress, b rest). On hybrid
SPECT/CT, the inferolateral
ischaemia could be localized to
the LCX (e , arrows), while the
anterior wall did not show any
relevant perfusion defect (d). This
indicates that treatment should be
targeted to the LCX to reduce
ischaemic burden of the LV
myocardium
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of procedural success and may help to decide between anter-
ograde or retrograde revascularization approaches [60].
Hybrid imaging for attenuation correction
The quality and accuracy of nuclear perfusion studies is often
affected by non-uniform photon attenuation, a common
source of image artefacts with often unpredictable patterns.
Whereas the accuracy of cardiac PET imaging has long
benefited from correction methods for tissue attenuation, in
SPECT imaging, commercial methods have only recently
been made available. Various techniques with different line
sources such as 241Am, 153Gd or 99mTc have been proposed
but yielded ambiguous results [61].
CT has shown promising results for attenuation correction
of SPECT allowing consistent image reading [62, 63]. The
radiation emitted from X-ray CT tubes is polychromatic com-
pared to the monoenergetic gamma photons from a radioac-
tive line source. Also, the flux of photons from a typical X-ray
tube is much higher than a conventional sealed radioactive
source. As a result transmission images for attenuation cor-
rection can be obtained within seconds using CT. However,
some pitfalls of CT-based attenuation correction should be
considered. For example, misalignment between SPECT and
the attenuation map can lead to artefacts in the apical, septal
and anterior walls that will appear as defects. It also can cause
overcorrection in the basal inferior and lateral segments. There
is evidence that mismatches along the other directions may
have a similar effect.
Although in SPECT photon energies are lower (70 keV
with 210Tl and 140 keV with 99mTc versus 511 keV with
positron-emitting radionuclides) and thus more susceptible
to attenuation, the pattern of attenuation is less predictable
than with PET. Therefore, with SPECT, the use of X-ray-
based attenuation correction is less well established. As a
result, most current dedicated cardiac SPECT systems are
not equipped with a low-dose CT facility for attenuation
correction. This can be overcome by using low-dose native
coronary artery calcium score (CACS) scans performed on a
stand-alone high-end CT device for attenuation correction of
the SPECT images. In contrast to present low-dose CT facil-
ities of hybrid SPECT/CT systems, CACS scans are ECG-
triggered and acquired during a single breath-hold. Hence, this
approach requires the use of interface software for manual
coregistration of SPECT and CT information to avoid
misalignment between both images (Fig. 5). The feasibility
and reproducibility of this method has been demonstrated by
Schepis and co-workers using CACS scans during full inspi-
ratory and expiratory breath-hold [64]. Parametric attenuation
A B
C D
Fig. 4 A 67-year-old patient
complained of new-onset chest
pain after percutaneous coronary
intervention (PCI) of his left
anterior descending artery (LAD).
a SPECT revealed a small
reversible perfusion defect in the
anterior basal myocardium
(arrows). b Hybrid SPECT/CT
shows stents in the LAD. The
anterior ischaemia (arrows) is not
subtended by the LAD, but by an
overstented and occluded
diagonal branch that is not visible
on CTangiography (dotted yellow
line). Review of coronary
angiography before (c) and after
(d) stenting of the LAD reveals
inadvertent closure of the
diagonal branch after PCI
(arrows)
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maps from CACS scans provided accurate and reliable atten-
uation correction of SPECT images resulting in a very good
correlation compared to the established attenuation correction
with the low-dose low-resolution CT facility included in the
hybrid SPECT/CT system.
Added value of CACS over SPECT alone
CACS provides an estimate of coronary atherosclerotic plaque
burden and correlates strongly with the overall amount of
coronary plaque (calcified and non-calcified) seen in post-
mortem examinations [65]. Assessment of the presence of
subclinical coronary atherosclerosis with CACS provides an
opportunity to identify asymptomatic patients who are at risk
for developing clinical CAD over the long term. Several studies
in asymptomatic subjects have consistently shown that CACS
provides accurate risk estimates for cardiac death and ischaemic
events beyond clinical parameters [66, 67]. These observations
have led to the implementation of CACS in current recommen-
dations for coronary risk assessment [68, 69]. Particularly in
patients at intermediate clinical risk, CACS may prove helpful
in more accurate risk stratification [70]. In addition to its
prognostic value, CACSmay also offer diagnostic information.
Coronary artery calcifications are almost always present with
angiographically significant CAD; thus, a CACS of 0 virtu-
ally excludes any significant angiographic CAD [71], partic-
ularly in asymptomatic patients. However, specificity and
PPV (23–62 %) are low and increase only moderately when
shifting the CACS cut-off from 0 to higher values.
While CACS is rarely used as a diagnostic test for CAD
detection, combined protocols with SPECT may be attractive
through integration of anatomical and functional information.
In a recent study by Schepis and colleagues the combination
of SPECTand CACS resulted in a significant improvement in
sensitivity and specificity for the diagnosis of angiographical-
ly significant CAD compared to SPECT alone [9]. The pres-
ence of high atherosclerotic burden in a symptomatic patient
with a normal or near-normal perfusion scan should alert the
reader to the possibility of MVD and a potential underestima-
tion of jeopardized myocardium by SPECTalone [72]. On the
other hand, an equivocal perfusion result in the presence of
zero CACS may raise the suspicion of an attenuation or
respiratory artefact justifying further CTCA to rule out CAD.
CACS may also add prognostic information to MPI.
Schenker and colleagues observed an independent stepwise
increase in death and MI rates with increasing CACS in 695
consecutive patients regardless of the presence or absence of
ischaemia on perfusion scan [73]. Among patients with nor-
mal perfusion, the annualized event rate in patients with a
CACS of 0 was 2.6 % versus 12.3 % in those with a CACS
≥1,000. Likewise, in patients with ischaemia, the annualized
event rate in those with a CACS of 0 was lower than among
patients with a CACS ≥1,000 (8.2 versus 22.1 %). Similar
results were obtained in 510 asymptomatic patients, albeit at a
lower CACS cut-off of 100 [74]. These results were not
(A) CT
(B) SPECT
(C) Fused SPECT/CT
Fig. 5 Coregistration of low-
dose CT (a) and SPECT (b)
for attenuation correction of
myocardial perfusion SPECT.
The fused SPECT/CT display
(c) allows one to identify
misalignment and correct it by
realigning the SPECTwith regard
to the CT images. (Reprinted with
permission from Springer [64])
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confirmed in a similar study performed in 1,153 very low-risk
patients undergoing SPECT and CACS with short follow-up
[75]. Chang and colleagues reported an incremental prognos-
tic value of CACS in 977 asymptomatic patients with normal
SPECT perfusion scans and a follow-up of 6.9 years [76].
There was a 3.6-fold relative increase for any cardiac event
and a 2.8-fold relative increase for death/MI when the CACS
was severe (>400) versus minimal (≤10). Separation of the
survival curves occurred at 3 years after initial testing for all
cardiac events and at 5 years for death/MI. This indicates that
if CACS is severe the “warranty period” of a normal SPECT
expires after 3–5 years. The REPROSPECT registry revealed
the added prognostic value of fusing CACS and myocardial
perfusion SPECT to allocate calcified vessels to their respec-
tive vascular territories [77]. Patients were divided into three
groups (1) MPI defect matched by calcification (CAC≥1) in
the subtending coronary artery, (2) unmatched MPI and CT
finding and (3) normal finding by MPI and CT. At the 35-
month follow-up, the most unfavourable outcome was ob-
served in patients with matched findings (36 versus 16 % in
the group with unmatched findings versus 0 % in the normal
group, p <0.001) (Fig. 6).
Perspectives of hybrid imaging
Hybrid imaging is increasingly contributing to the develop-
ment of imaging strategies which go beyond the assessment of
myocardial perfusion. Furthermore, the use of other modali-
ties (e.g. cardiac MRI) may expand existing indications for
hybrid imaging. A number of novel hybrid imaging
approaches hold promise to make their way into clinical
practice or are already being used in very specialized centres.
Cardiac resynchronization therapy (CRT) has established
itself as an important therapeutic option to improve symptoms
and prognosis in heart failure patients. Unfortunately, CRT
non-responder rates are still high (approximately 30 %), par-
ticularly in patients with ischaemic heart disease. Therefore,
efficient tools to predict CRT success and improve patient
selection are urgently needed. Hybrid imaging may combine
venous anatomy from CT (by scanning in the venous phase)
with viability information from SPECT. This approach may
allow visualization of venous morphology and identification
of candidate veins for percutaneous lead insertion, while at the
same time viability in this territory is ascertained [78]. It is
likely that patients in whom the LV lead is placed in a non-
viable territory may not respond to CRT. Furthermore, me-
chanical LV dyssynchrony can be quantified by phase analysis
of gated perfusion SPECT studies [79]. Potentially, this ap-
proach could prove useful to optimize CRT.
Experimental approaches in human and animal studies
have used hybrid imaging to colocalize anatomical informa-
tion with (mainly radionuclide) signals from molecular path-
ways that precede or underlie changes in morphology or
pathophysiology. Examples are the use of neuronal imaging
to identify subjects at risk for ventricular arrhythmia, the
development of compounds targeting plaque vulnerability
before rupture and subsequent MI, the targeting of
biomechanisms which precede LV remodelling and heart fail-
ure development, the development of reporter gene imaging
techniques and the implementation of cell labelling for imag-
ing of engraftment after transplantation [80, 81].
Conclusion
A comprehensive appraisal of anatomical and functional as-
pects of disease is crucial in cardiac imaging, particularly for
the appropriate management of patients with known or
suspected CAD. Hybrid imaging has entered the clinical arena
in the past few decades and is facing increasing interest for
clinical and research purposes as it allows one to obtain
combined anatomical and functional information of cardiac
pathology through non-invasive multimodality imaging. Hy-
brid SPECT/CT imaging is promoted by the dissemination of
hybrid devices, the development of improved devices and
protocols with reduced radiation exposure and shorter acqui-
sition times, and the implementation of efficient and dedicated
image reconstruction and fusion algorithms. The combined
anatomical and functional information on CAD extent and
severity may facilitate diagnosis, improve risk stratification
and guide appropriate management strategies (particularly by
selecting patients that may benefit from revascularization
procedures) in particular subsets of CAD patients. However,
the added costs and increased radiation exposure of hybrid
Fig. 6 Kaplan-Meier survival curves free ofMACE according to normal,
unmatched andmatched findings of SPECTandCACS onCT. (Reprinted
with permission from Oxford University Press [77])
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imaging studies must be considered before ordering such tests,
and larger prospective studies are needed to address issues
such as incremental clinical value, impact on patient manage-
ment and outcome and cost-effectiveness. Nevertheless, the
use of hybrid imaging in other fields of cardiology may
enhance our pathophysiological understanding of cardiac pa-
thologies by linking morphological changes with underlying
biochemical or subsequent functional alterations and thereby
open avenues for hybrid imaging in heart failure, CRT, stem
cell and gene therapy, plaque imaging, cardiac remodelling
and regenerative medicine.
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